Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Teclistamab in Relapsed/Refractory Multiple Myeloma: Real-World Outcomes at a Single Academic Center in the Midwest

Adam Stepanovic, Rafat Abonour, Mohammad Abu Zaid, Sherif Farag, Kelvin P. Lee, Attaya Suvannasankha

Blood (2023) 142 (Supplement 1): 7359.

https://doi.org/10.1182/blood-2023-183085

Published: 2023

Journal Articles

Characterization of Anthropometric Changes in Patients with Relapsed/Refractory Myeloma Treated with BCMA Bispecific Antibody Teclistamab

Setarah Mohammad Nader, S. Tyler Jines, Christopher Collier, Teresa Zimmers, Rafat Abonour, Sherif Farag, Mohammad Abu Zaid, Kelvin P. Lee, Attaya Suvannasankha

Blood (2023) 142 (Supplement 1): 6683.

https://doi.org/10.1182/blood-2023-182754

Published: 2023

Journal Articles

Phase I First-in-Human Study on the Feasibility, Safety, and Antitumor Activity of CD4-Redirected Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with CD4+ T-Cell Malignancies (TCM)

Rita Assi, Nabil Hagag, Sherif Farag, Robert V.B. Emmons, Allie Carter, Magdalena Czader, Rafat Abonour, Lionel Apetoh, Yupo Ma, Huda S. Salman

Blood (2023) 142 (Supplement 1): 6854.

https://doi.org/10.1182/blood-2023-180111

Published: 2023

Journal Articles

Phase 2 Study of Carfilzomib and Bone Metabolism in Patients with Relapsed Multiple Myeloma

Attaya Suvannasankha, MD, Rafat Abonour, MD, Sherif Farag, MD PhD, Rebecca W. Silbermann, MD, Sariya Wongsaengsak, MD, Mary Helen Cangany, RN, Anita Rush-Taylor, RN, Mark Tann, MD, Sandra K Althouse, PhD, Susan M Perkins, PhD, G David Roodman, MD PhD

Blood (2017) 130 (Supplement 1): 1826.

https://doi.org/10.1182/blood.V130.Suppl_1.1826.1826

Published: 2017

Journal Articles

Phase I/II Study of Lenalidomide and High Dose Melphalan As Preparative Regimen in Autologous Transplant in Myeloma: Report of Phase II Efficacy and Safety Data

Attaya Suvannasankha, MD, Sherif Farag, MD PhD, Rebecca Silbermann, MD, Mary Cangany, RN, Anita Rush-Taylor, RN, Robin O'Bryant, RN, Lisa Wood, RN, Jean Pearson, Sarah Singleton, Andrea Bradley, Sandra Althouse, Susan Perkins, PhD, Deb Estes, RN, Rafat Abonour, MD

Blood (2015) 126 (23): 3193.

https://doi.org/10.1182/blood.V126.23.3193.3193

Published: 2015

Journal Articles

Single Center Retrospective Comparison of Gvhd Preventive Regimens after Cy/Flu Minimal Intensity Allotransplantation

Praveen Ranganath, MBBS, Michael J. Robertson, MD, Rafat Abonour, MD, Jennifer E. Schwartz, MD FRCP(C), Sherif Farag, MBBS, PhD, Lisa l Wood, RN, Patrick Kiel, PharmD, Robert Nelson

Blood (2014) 124 (21): 5874.

https://doi.org/10.1182/blood.V124.21.5874.5874

Published: 2014

Journal Articles

A Phase I/II Trial Combining High-Dose Lenalidomide with Melphalan and Autologous Transplant for Multiple Myeloma: A Report of the Phase I Dose-Finding Study.

Attaya Suvannasankha, MD, Sherif Farag, MD, PhD, FRACP, FRCPA, Rebecca Silbermann, M.D., Robin Obryant, RN, Lisa l Wood, RN, Abigail Huljak, Angie Secrest, Colin D. Crean, Rafat Abonour, MD

Blood (2012) 120 (21): 3146.

https://doi.org/10.1182/blood.V120.21.3146.3146

Published: 2012

Journal Articles

Assessment of Free Light Chains in the Ascites and Pleural Effusion in Patients with Multiple Myeloma: A Report of 2 Cases

Sawsan Rashdan, MD, Sherif Farag, MD, PhD, FRACP, FRCPA, Rafat Abonour, MD, Attaya Suvannasankha, MD

Blood (2011) 118 (21): 5078.

https://doi.org/10.1182/blood.V118.21.5078.5078

Published: 2011

Journal Articles

A Potential Biomarker Panel of Multiple Myeloma Identified Using Label-Free Mass Spectrometry-Based Quantitative Proteomics

Attaya Suvannasankha, MD, Colin D. Crean, Heather M. Sahm, Rafat Abonour, MD, Sherif Farag, MD, PhD, FRACP, FRCPA, Mu Wang, PhD

Blood (2011) 118 (21): 2890.

https://doi.org/10.1182/blood.V118.21.2890.2890

Published: 2011

Journal Articles

The Outcome of the Combination of Tacrolimus, Sirolimus, and ATG for GvHD Prophylaxis on Allogeneic Stem Cell Transplantation From Matched Unrelated Donors

Yaser Homsi, MD, Dareen Alwan, MD, Patrick Kiel, PharmD, Lindsay Rosenbeck, PharnD, Srivastava Shivani, MD, Jennifer E. Schwartz, MD, FRCP(C), Robert P. Nelson, Jr., MD, Rafat Abonour, MD, Michael Robertson, MD, Sherif Farag, MD, PhD, FRACP, FRCPA

Blood (2010) 116 (21): 2345.

https://doi.org/10.1182/blood.V116.21.2345.2345

Published: 2010

Journal Articles

IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data

Don M Benson, Jr, MD, Courtney E Bakan, Swaminathan Padmanaban, Rafat Abonour, MD, Attaya Suvannasankha, Sundar Jagannath, Ajai Chari, MD, David Clever, Chidimma Kalu, Shauna Collins, Yousef Alghothani, Craig C. Hofmeister, MD, Yvonne Efebera, MD, Stephane Blanchet, Michael A. Caligiuri, MD, Sherif Farag, MD, PhD, FRACP, FRCPA

Blood (2010) 116 (21): 1966.

https://doi.org/10.1182/blood.V116.21.1966.1966

Published: 2010

Journal Articles

Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients

Attaya Suvannasankha, Sherif Farag, MD, PhD, FRACP, FRCPA, Robin Obryant, RN, Lisa l Wood, RN, Nicole Porter, Rafat Abonour, MD

Blood (2010) 116 (21): 1970.

https://doi.org/10.1182/blood.V116.21.1970.1970

Published: 2010

Journal Articles

Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia

Craig C. Hofmeister, MD, Mindy A Bowers, BS, Seungsoo Lee, MS, Mitch A. Phelps, PhD, Don M Benson, Jr, MD, PhD, Eric H. Kraut, MD, William J Hicks, MD, Deidre Deam, RN, Amy J Johnson, PhD, Sherif Farag, MD, PhD, FRACP, FRCPA, Jeffrey A. Jones, MD, MPH, John C. Byrd, MD

Blood (2010) 116 (21): 1933.

https://doi.org/10.1182/blood.V116.21.1933.1933

Published: 2010

Journal Articles

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Alter the Hematopoietic Niche and Treatment In Healthy Volunteers Results In Mobilization of CD34 + Cells, Hematopoietic Colony Forming Cells, and Endothelial Colony Forming Cells

Jonathan Hoggatt, PhD, Brahmananda Reddy Chitteti, PhD, Vani Krishna, Ph.D., Sherif Farag, MD, PhD, FRACP, FRCPA, Magdalena Czader, MD, Mervin C. Yoder, MD, Edward Srour, PhD, Louis M. Pelus, PhD

Blood (2010) 116 (21): 556.

https://doi.org/10.1182/blood.V116.21.556.556

Published: 2010

Journal Articles

Clinical Activity of a Novel Multiple Tyrosine Kinase and Aurora Kinase Inhibitor, ENMD-2076, Against Multiple Myeloma: Interim Phase I Trial Results

Sherif Farag, MD, PhD, Shuhong Zhang, PhD, Attaya Suvannasankha, MD, Jing Liang, MD, Robyn O'Bryant, RN, Wood Lisa, RN, Sushil Gupta, PhD, Mark Bray, PhD, Carolyn Fowler Sidor, MD, Rafat Abonour, MD

Blood (2010) 116 (21): 1957.

https://doi.org/10.1182/blood.V116.21.1957.1957

Published: 2010

Journal Articles

Assessment of the Performance of Serum Heavy Chains Immunoassay to Monitor Response to Treatment and Its Correlation with Other Tumor Measurements In Serial Samples From Patients with Newly Diagnosed MM

Attaya Suvannasankha, MD, Sherif Farag, MD, PhD, FRACP, FRCPA, Stephen Harding, PhD, Brian GM Durie, MD, Rafat Abonour, MD

Blood (2010) 116 (21): 2986.

https://doi.org/10.1182/blood.V116.21.2986.2986

Published: 2010

Journal Articles

Infusion of Large Number of Circulating Myeloma Cells Does Not Influence the Survival of Patients Undergoing Autologous Stem Cell Transplantation.

Rafat Abonour, Hayley Knollman, Attaya Suvannasankha, MD, Menggang Yu, Rebecca Britton, Shivani Srivastava, MD, Robert P. Nelson, Jr., MD, Jennifer E. Schwartz, MD, FRCP(C), Michael Robertson, MD, Kenneth Cornetta, MD, Sherif Farag, MBBS, PhD

Blood (2009) 114 (22): 1224.

https://doi.org/10.1182/blood.V114.22.1224.1224

Published: 2009

Journal Articles

The Role of the Antiapoptotic Protein c-FLIP in Multiple Myeloma.

Colin D. Crean, Genglin Zhang, Lauren B VanRyckeghem, BS, Helmut Hanenberg, Sherif Farag, MBBS, PhD, Rafat Abonour, Attaya Suvannasankha, MD

Blood (2009) 114 (22): 1966.

https://doi.org/10.1182/blood.V114.22.1966.1966

Published: 2009

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Compared to Chemotherapy Only in Acute Myeloid Leukemia (AML) Patients 60 Years and Older: A Center for International Blood and Marrow Transplantation Research (CIBMTR)/ Cancer and Leukemia Group B (CALGB) Study.

Sherif Farag, MD, PhD, Kati Maharry, MAS, Waleska S. Perez, MPH, Mei-Jie Zhang, PhD, John F. DiPersio, MD, PhD, Donald Bunjes, MD, Guido Marcucci, M.D., Maria R. Baer, M.D., Richard A. Larson, MD, Martin Tallman, MD, Clara D. Bloomfield, M.D., Daniel J. Weisdorf, MD

Blood (2009) 114 (22): 657.

https://doi.org/10.1182/blood.V114.22.657.657

Published: 2009

Journal Articles

Multiple Myeloma Derived Factors Generate Tolerogenic Dendritic Cells by Activation of STAT3: A Potential Target for Immunotherapy.

Yaser Homsi, MD, Li Chen, MD, Shuhong Zhang, PhD, Jing Liang, Attaya Suvannasankha, MD, Rafat Abonour, MD., Sherif Farag, MD, PhD

Blood (2009) 114 (22): 3031.

https://doi.org/10.1182/blood.V114.22.3031.3031

Published: 2009

NARROW

Teclistamab in Relapsed/Refractory Multiple Myeloma: Real-World Outcomes at a Single Academic Center in the Midwest

Characterization of Anthropometric Changes in Patients with Relapsed/Refractory Myeloma Treated with BCMA Bispecific Antibody Teclistamab

Phase I First-in-Human Study on the Feasibility, Safety, and Antitumor Activity of CD4-Redirected Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with CD4+ T-Cell Malignancies (TCM)

Phase 2 Study of Carfilzomib and Bone Metabolism in Patients with Relapsed Multiple Myeloma

Phase I/II Study of Lenalidomide and High Dose Melphalan As Preparative Regimen in Autologous Transplant in Myeloma: Report of Phase II Efficacy and Safety Data

Single Center Retrospective Comparison of Gvhd Preventive Regimens after Cy/Flu Minimal Intensity Allotransplantation

A Phase I/II Trial Combining High-Dose Lenalidomide with Melphalan and Autologous Transplant for Multiple Myeloma: A Report of the Phase I Dose-Finding Study.

Assessment of Free Light Chains in the Ascites and Pleural Effusion in Patients with Multiple Myeloma: A Report of 2 Cases

A Potential Biomarker Panel of Multiple Myeloma Identified Using Label-Free Mass Spectrometry-Based Quantitative Proteomics

The Outcome of the Combination of Tacrolimus, Sirolimus, and ATG for GvHD Prophylaxis on Allogeneic Stem Cell Transplantation From Matched Unrelated Donors

IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data

Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients

Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Alter the Hematopoietic Niche and Treatment In Healthy Volunteers Results In Mobilization of CD34 + Cells, Hematopoietic Colony Forming Cells, and Endothelial Colony Forming Cells

Clinical Activity of a Novel Multiple Tyrosine Kinase and Aurora Kinase Inhibitor, ENMD-2076, Against Multiple Myeloma: Interim Phase I Trial Results

Assessment of the Performance of Serum Heavy Chains Immunoassay to Monitor Response to Treatment and Its Correlation with Other Tumor Measurements In Serial Samples From Patients with Newly Diagnosed MM

Infusion of Large Number of Circulating Myeloma Cells Does Not Influence the Survival of Patients Undergoing Autologous Stem Cell Transplantation.

The Role of the Antiapoptotic Protein c-FLIP in Multiple Myeloma.

Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Compared to Chemotherapy Only in Acute Myeloid Leukemia (AML) Patients 60 Years and Older: A Center for International Blood and Marrow Transplantation Research (CIBMTR)/ Cancer and Leukemia Group B (CALGB) Study.

Multiple Myeloma Derived Factors Generate Tolerogenic Dendritic Cells by Activation of STAT3: A Potential Target for Immunotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only